small molecule clinical trial intelligence

Efficacy and Safety of Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma

Efficacy and Safety of Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma is a PHASE2 clinical asset sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University in Soft Tissue Sarcoma. SEO and diligence focus: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients

Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients is a PHASE4 clinical asset sponsored by Qilu Hospital of Shandong University in Delirium. SEO and diligence focus: midazolam, Dexmedetomidine, Fentanyl, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome is a PHASE3 clinical asset sponsored by Biomed Industries, Inc. in Rett Syndrome. SEO and diligence focus: Bionetide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Taiho Oncology, Inc. in Advanced Solid Tumors. SEO and diligence focus: TAS-116, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)

A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993) is a PHASE2 clinical asset sponsored by National Cancer Institute (NCI) in Colorectal Cancer. SEO and diligence focus: becatecarin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas is a PHASE1 clinical asset sponsored by Silenseed Ltd in Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer. SEO and diligence focus: siG12D LODER, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies is a PHASE1 clinical asset sponsored by New Mexico Cancer Research Alliance in Advanced Solid Tumor Malignancies. SEO and diligence focus: 5-azacytidine, erlotinib, Erlotinib PO and Vidaza IV, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Eikon Therapeutics in Advanced Solid Tumors. SEO and diligence focus: EIK1004-001 (IMP1707-001), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Tumor Pathway Activations Inhibited by Dovitinib. SEO and diligence focus: Dovitinib (TKI258), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies is a PHASE2 clinical asset sponsored by Franziska Wachter in Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml. SEO and diligence focus: Decitabine, Filgrastim, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers is a PHASE1 clinical asset sponsored by G2GBio, Inc. in Alzheimer Disease. SEO and diligence focus: GB-5001, Placebo, Oral cohort, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD is a PHASE2 clinical asset sponsored by Pfizer in Alzheimer Disease. SEO and diligence focus: bapineuzumab, bapineuzumab, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial is a PHASE2 clinical asset sponsored by University of Edinburgh in Motor Neuron Disease, Amyotrophic Lateral Sclerosis. SEO and diligence focus: Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution, Amantadine Hydrochloride Oral Solution, Tacrolimus 1Mg Cap, Placebo capsule, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Ginger and the Microbiota-gut-brain Connection in Sciatic Pain Individuals

Ginger and the Microbiota-gut-brain Connection in Sciatic Pain Individuals is a PHASE2 clinical asset sponsored by Leslie Shen in Neuropathic Pain, Sciatic Pain. SEO and diligence focus: Placebo, Ginger, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients.

Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients. is a NA clinical asset sponsored by Sahlgrenska University Hospital in Non-alcoholic Fatty Liver Disease, Morbid Obesity. SEO and diligence focus: Ursodeoxycholic Acid (UDCA), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease

Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease is a NA clinical asset sponsored by Bioray Laboratories in Sickle Cell Disease. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma is a PHASE1 clinical asset sponsored by Nanjing IASO Biotechnology Co., Ltd. in B-cell Non-Hodgkin's Lymphoma. SEO and diligence focus: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma is a PHASE1 clinical asset sponsored by AbbVie in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma. SEO and diligence focus: Navitoclax, Chemotherapy, Venetoclax, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide

A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin Lispro Protamine Suspension, Insulin Glargine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2 is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: liraglutide, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension is a PHASE4 clinical asset sponsored by United Therapeutics in Pulmonary Arterial Hypertension. SEO and diligence focus: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis is a PHASE3 clinical asset sponsored by Azafaros B.V. in Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis. SEO and diligence focus: AZ-3102, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration is a PHASE2 clinical asset sponsored by University Hospital Hradec Kralove in Ischemic Stroke. SEO and diligence focus: Albumin infusion, Placebo Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Implementing and Evaluating ActionADE to Transform Medication Safety Among Patients With an Adverse Drug Event Due to Non-Adherence

Implementing and Evaluating ActionADE to Transform Medication Safety Among Patients With an Adverse Drug Event Due to Non-Adherence is a NA clinical asset sponsored by University of British Columbia in Adverse Drug Event, Non-Adherence, Medication. SEO and diligence focus: ActionADE, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer

The Effect of Perioperative Lidocaine Intravenous Infusion on Neutrophil Extracellular Trapping After Surgery for Stomach Cancer is a NA clinical asset sponsored by The Catholic University of Korea in Gastric Cancer. SEO and diligence focus: Lidocaine, normal saline, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma

Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic Melanoma is a PHASE2 clinical asset sponsored by University of Kansas Medical Center in Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma. SEO and diligence focus: Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis is a PHASE2 clinical asset sponsored by NYU Langone Health in Focal Segmental Glomerulosclerosis. SEO and diligence focus: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies is a PHASE1 clinical asset sponsored by National Cancer Institute (NCI) in Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute. SEO and diligence focus: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies is a PHASE1 clinical asset sponsored by AbbVie (prior sponsor, Abbott) in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia. SEO and diligence focus: ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia. SEO and diligence focus: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia. SEO and diligence focus: Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology is a PHASE3 clinical asset sponsored by Lantheus Biosciences Ltd. in Alzheimer Disease. SEO and diligence focus: Florbetaben (BAY94-9172), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir

Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir is a PHASE2 clinical asset sponsored by Fred Hutchinson Cancer Center in Human Immunodeficiency Virus I Infection. SEO and diligence focus: Mycophenolate Mofetil 500Mg Tab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects

An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects is a PHASE1 clinical asset sponsored by Hoffmann-La Roche in Healthy Volunteers. SEO and diligence focus: Risdiplam, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26") is a PHASE1 clinical asset sponsored by Editas Medicine, Inc. in Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital. SEO and diligence focus: EDIT-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced Liver Cancer is a NA clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Liver Cancer. SEO and diligence focus: QY-1-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Mechanisms of Hypoglycemia Associated Autonomic Failure

Mechanisms of Hypoglycemia Associated Autonomic Failure is a PHASE2 clinical asset sponsored by Albert Einstein College of Medicine in Diabetes Mellitus, Hypoglycemia, Autonomic Failure. SEO and diligence focus: naloxone, fructose, exercise, Morphine sulfate, Epinephrine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus is a PHASE2 clinical asset sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in Type 2 Diabetes Mellitus. SEO and diligence focus: TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

SAR438544 - Clinical & Exploratory Pharmacology

SAR438544 - Clinical & Exploratory Pharmacology is a PHASE1 clinical asset sponsored by Sanofi in Type 1 Diabetes Mellitus. SEO and diligence focus: SAR438544, r-glucagon, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus

A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 1. SEO and diligence focus: LY2963016, Lantus, Insulin Lispro, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2

Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 is a PHASE1 clinical asset sponsored by Vanderbilt University in Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension. SEO and diligence focus: Trimethaphan, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients is a PHASE3 clinical asset sponsored by Eisai Co., Ltd. in Gastroesophageal Reflux Disease. SEO and diligence focus: Rabeprazole, Rabeprazole, Rabeprazole, Rabeprazole, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh

Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh is a PHASE4 clinical asset sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh in Spondyloarthritis. SEO and diligence focus: Tofacitinib 5 mg,, Etanercept, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer is a PHASE3 clinical asset sponsored by Jiangsu HengRui Medicine Co., Ltd. in Non-Small Cell Lung Cancer With HER2- Mutations. SEO and diligence focus: SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics

Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics is a NA clinical asset sponsored by Prisma Health-Upstate in Diabetic Foot Infections. SEO and diligence focus: Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: AZD1656, Gemfibrozil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)

Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH) is a PHASE2 clinical asset sponsored by Central Hospital, Nancy, France in Non-alcoholic Steatohepatitis. SEO and diligence focus: PET scan of 68Ga-FAPI, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Therapeutic Effect and Quality of Life After Local Injection of Steroid VS. Glucose 5% for Carpal Tunnel Syndrome : Double-blinded Clinical Trial

The Therapeutic Effect and Quality of Life After Local Injection of Steroid VS. Glucose 5% for Carpal Tunnel Syndrome : Double-blinded Clinical Trial is a PHASE4 clinical asset sponsored by Assiut University in Carpal Tunnel Syndrome. SEO and diligence focus: Dexamethasone, Glucose Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in MDS, AML. SEO and diligence focus: Decitabine, Cytarabine, aclacinomycin, Granulocyte colony-stimulating factor, HLA haploidentical mononuclear cells infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia is a PHASE1 clinical asset sponsored by Tara Lin in Acute Lymphocytic Leukemia, Acute Myeloid Leukemia. SEO and diligence focus: Daunorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies is a PHASE2 clinical asset sponsored by H. Lee Moffitt Cancer Center and Research Institute in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma. SEO and diligence focus: Fludarabine, Melphalan, Total Body Irradiation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia

Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia is a PHASE2 clinical asset sponsored by Hansoh BioMedical R&D Company in Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease. SEO and diligence focus: HS-20106, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy)

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy) is a PHASE2 clinical asset sponsored by St. Petersburg State Pavlov Medical University in Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia. SEO and diligence focus: Ruxolitinib, Abatacept (Orencia), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers is a PHASE1 clinical asset sponsored by TauRx Therapeutics Ltd in Alzheimer's Disease. SEO and diligence focus: TRx0037, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease is a PHASE1 clinical asset sponsored by NKGen Biotech, Inc. in Moderate Alzheimer Disease. SEO and diligence focus: SNK01, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease. is a PHASE2 clinical asset sponsored by Stanford University in Alzheimer Disease. SEO and diligence focus: Bumetanide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease is a PHASE1 clinical asset sponsored by University Medical Center Groningen in Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease, Mild Cognitive Impairment. SEO and diligence focus: [18F]MC225, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Amyotrophic Lateral Sclerosis. SEO and diligence focus: BLZ945, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis is a PHASE1 clinical asset sponsored by Newron Sweden AB in Amyotrophic Lateral Sclerosis. SEO and diligence focus: sNN0029 infusion solution, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) is a PHASE1 clinical asset sponsored by Therapeutic Advances in Childhood Leukemia Consortium in Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute. SEO and diligence focus: EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes Mellitus, Type 2. SEO and diligence focus: Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus is a PHASE4 clinical asset sponsored by Command Hospital, India in Type 1 Diabetes. SEO and diligence focus: Insulin, Sitagliptin, Exenatide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET

The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET is a PHASE2 clinical asset sponsored by University of Aarhus in Healthy. SEO and diligence focus: native glp-1 (7-36), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes is a PHASE4 clinical asset sponsored by Fundación Fernández-Cruz in Type 2 Diabetes. SEO and diligence focus: Liraglutide + metformin, Glimepiride + metformin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: semaglutide, liraglutide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis is a PHASE3 clinical asset sponsored by Janssen Research & Development, LLC in Colitis, Ulcerative. SEO and diligence focus: Golimumab, Infliximab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) is a PHASE3 clinical asset sponsored by Principia Biopharma, a Sanofi Company in Immune Thrombocytopenia. SEO and diligence focus: Rilzabrutinib, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma

A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma is a PHASE4 clinical asset sponsored by West Penn Allegheny Health System in Asthma. SEO and diligence focus: Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases

Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Neuroectodermal Tumor, Brain Metastases, Advanced Cancer. SEO and diligence focus: Valproate, Etoposide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies

A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies is a PHASE2 clinical asset sponsored by Northwestern University in Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV. SEO and diligence focus: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection is a PHASE1 clinical asset sponsored by University of Minnesota in Recurrent Clostridioides Difficile Infection, Colonic Surgery. SEO and diligence focus: Orally administered preparation of fecal microbiota (MTP-101P), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Diabetes Mellitus, Type 2. SEO and diligence focus: MK-1403 + additive coformulation, Placebo + additive coformulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients is a PHASE3 clinical asset sponsored by Lindner Center of HOPE in Binge Eating Disorder Associated With Obesity. SEO and diligence focus: Zonegran, sugar pill, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myelogenous Leukemia. SEO and diligence focus: Plerixafor, Clofarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors is a PHASE1 clinical asset sponsored by St. Jude Children's Research Hospital in Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome. SEO and diligence focus: Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial is a PHASE3 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years). SEO and diligence focus: Venetoclax, Azacitidine, Homoharringtonine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies is a PHASE1 clinical asset sponsored by Incyte Corporation in Solid Tumors. SEO and diligence focus: INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease is a PHASE2 clinical asset sponsored by Sunnybrook Health Sciences Centre in Hippocampal Hyperactivation, Prodromal Alzheimer Disease. SEO and diligence focus: Levetiracetam (LEV), Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD is a PHASE2 clinical asset sponsored by AstraZeneca in Alzheimer´s Disease. SEO and diligence focus: AZD1446, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE) is a PHASE3 clinical asset sponsored by Eidos Therapeutics, a BridgeBio company in Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis. SEO and diligence focus: Acoramidis (AG10), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer

Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer is a PHASE2 clinical asset sponsored by UNC Lineberger Comprehensive Cancer Center in Bladder Cancer. SEO and diligence focus: Pembrolizumab, Entinostat, Procedure/Surgery, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I) is a PHASE1 clinical asset sponsored by University of Utah in Spinal Muscular Atrophy Type I. SEO and diligence focus: Valproic Acid and Levocarnitine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma is a PHASE1 clinical asset sponsored by Celgene in Multiple Myeloma. SEO and diligence focus: ACY-1215, lenalidomide, Dexamethasone, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL

A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL is a PHASE1 clinical asset sponsored by Ruijin Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: ABO2203 Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia is a PHASE1 clinical asset sponsored by Bioray Laboratories in Beta-Thalassemia. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia. SEO and diligence focus: Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Relapsed Adult AML, Refractory AML. SEO and diligence focus: anti-CLL-1 CAR NK cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study) is a PHASE1 clinical asset sponsored by University of Alabama at Birmingham in Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular. SEO and diligence focus: Retifanlimab, INCAGN02385, INCAGN02390, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes is a PHASE2 clinical asset sponsored by University of British Columbia in Type 2 Diabetes, Postprandial Hypotension. SEO and diligence focus: Acarbose, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Type 2 Diabetes, Overweight, Obesity. SEO and diligence focus: Tirzepatide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin detemir, Insulin NPH, Diet/exercise, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia is a PHASE2 clinical asset sponsored by Ain Shams University in Transfusion Dependent Beta Thalassemia. SEO and diligence focus: Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment? is a PHASE3 clinical asset sponsored by Azienda Ospedaliero-Universitaria di Parma in Dysglycemia, Cognitive Deficit. SEO and diligence focus: Exenatide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

The Effects of Neprilysin on Glucagon-like Peptide-1

The Effects of Neprilysin on Glucagon-like Peptide-1 is a PHASE4 clinical asset sponsored by Nicolai Jacob Wewer Albrechtsen in Diabetes, Heart Failure. SEO and diligence focus: Entresto, Sitagliptin 100mg, Placebos, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning

Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning is a NA clinical asset sponsored by University of Aarhus in Metabolism, Fatty Liver. SEO and diligence focus: Somatropin and pegvisomant, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition: Adaptive, Multicenter, Placebo-controlled, Randomised, Double Blind Trial in a Rare Disorder

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition: Adaptive, Multicenter, Placebo-controlled, Randomised, Double Blind Trial in a Rare Disorder is a PHASE2 clinical asset sponsored by Assistance Publique Hopitaux De Marseille in Spinal Cord Injury. SEO and diligence focus: Riluzole, Placebo, Blood Samples, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma

A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma is a PHASE2 clinical asset sponsored by Columbia University in Adult T Cell Leukemia/Lymphoma. SEO and diligence focus: Lenalidomide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) is a PHASE3 clinical asset sponsored by Ionis Pharmaceuticals, Inc. in Hereditary Angioedema. SEO and diligence focus: Donidalorsen, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets

Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets is a EARLY_PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Advanced Cancer. SEO and diligence focus: Temsirolimus, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration is a PHASE1 clinical asset sponsored by Fuzhou General Hospital in NSCLC. SEO and diligence focus: QYJD Compound Preparation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: small molecule